In LC_01T patient with lung cancer, the tumor recurred despite receiving platinum-doublet chemotherapy after tumor removal surgery and was prescribed the ALK-targeted drug alectinib, showing a partial response (PR) in which the tumor size decreased (Fig. 8A). The gene discussed is ALK; the disease is neoplasm.